Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin in T2DM with CKD and CV Risk
NCT03315143Phase 3Terminated
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Dec 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 45
01
Overview
A Phase 3 trial of sotagliflozin in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by Lexicon Pharmaceuticals, Inc.. Started Dec 2017; status: terminated.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03315143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315143.